Late Stage Pipeline And Biosimilar Pressure Will Constrain Long Term Earnings Power

Catalysts

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global biopharmaceutical company focused on innovative central nervous system and respiratory medicines alongside a large generics and biosimilars portfolio.

What are the underlying business or industry changes driving this perspective?

• Heavy reliance on a narrow set of growth engines such as AUSTEDO, UZEDY and AJOVY, in indications where underdiagnosis and undertreatment are being actively addressed across the industry, could expose Teva to future competitive launches and reimbursement tightening that may cap pricing power and slow top line expansion, pressuring revenue growth targets.
• The late stage pipeline concentration in complex neuro and immunology assets, including olanzapine LAI, duvakitug and emrusolmin, increases execution and regulatory risk at a time when trial sizes and timelines are expanding across the industry. Any delay or failure could materially undercut the projected $11 billion in peak sales and weigh on long term earnings.
• Expected expansion of biosimilars in the U.S. and Europe, while positive for patient access, is likely to accelerate price compression and tender driven competition. This could erode margins faster than Teva can offset with volume and operational savings, constraining gross margin and operating margin progression.
• Transformation and cost reduction programs aimed at delivering $700 million of savings by 2027 depend on sustained restructuring, footprint optimization and automation at a time of increasing regulatory and quality scrutiny. There is a risk that incremental compliance and inflationary costs dilute the anticipated uplift in operating margins and net income.
• Strategic uncertainty around TAPI divestiture and broader geopolitical shifts in global supply chains may require less favorable sale terms or higher ongoing sourcing costs. This could limit deleveraging capacity and raise the cost base for key products, which would dampen free cash flow generation and slow net debt reduction.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Teva Pharmaceutical Industries compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Teva Pharmaceutical Industries's revenue will remain fairly flat over the next 3 years.
• The bearish analysts assume that profit margins will increase from 9.0% today to 12.6% in 3 years time.
• The bearish analysts expect earnings to reach $2.2 billion (and earnings per share of $2.24) by about July 2029, up from $1.6 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $3.3 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 23.6x on those 2029 earnings, up from 23.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 14.9x.
• The bearish analysts expect the number of shares outstanding to grow by 1.51% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.58%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The company has now delivered 11 consecutive quarters of revenue growth, is tracking toward mid single digit annual revenue expansion through 2027 and is increasingly driven by high growth innovative brands such as AUSTEDO, UZEDY and AJOVY, which could sustain or accelerate top line growth rather than lead to a decline in revenue.
• AUSTEDO has secured an IRA agreement that management says is consistent with prior expectations, while still supporting a 2027 revenue target of 2.5 billion dollars and peak sales above 3 billion dollars, and this combination of volume growth in an underdiagnosed market and pricing visibility may support higher than expected earnings and net margins.
• The late stage pipeline, including olanzapine LAI, the dual action rescue inhaler, duvakitug, emrusolmin and the anti IL 15 antibody, targets large, chronic indications with over 11 billion dollars of potential peak sales, so successful execution could create durable new revenue streams and structurally raise operating margins and long term earnings power.
• The transformation program targeting 700 million dollars of net savings by 2027, coupled with a portfolio shift toward higher margin innovative products, has already lifted non GAAP gross margin to 55.3 percent and operating margin to 28.9 percent, suggesting further operating leverage that could expand net margins even if pricing pressure emerges in generics and biosimilars.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Teva Pharmaceutical Industries is $33.08, which represents up to two standard deviations below the consensus price target of $40.9. This valuation is based on what can be assumed as the expectations of Teva Pharmaceutical Industries's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $33.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $17.4 billion, earnings will come to $2.2 billion, and it would be trading on a PE ratio of 23.6x, assuming you use a discount rate of 8.6%.
• Given the current share price of $31.0, the analyst price target of $33.08 is 6.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.